Your session is about to expire
← Back to Search
Parsaclisib Combinations for B-Cell Cancers
Study Summary
This trial is for people who have already been taking parsaclisib in other studies, and will continue to take it either alone or with other drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 88 Patients • NCT02018861Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am willing and able to follow the study's schedule and treatment plans.I can get parsaclisib alone or with other specific treatments outside a study.You are willing to prevent pregnancy or becoming a father during the study.My condition is stable as confirmed by my doctor.I am benefiting from my current cancer treatment involving parsaclisib alone or with other specific drugs.
- Group 1: parsaclisib + ibrutinib
- Group 2: parsaclisib + ruxolitinib
- Group 3: parsaclisib
- Group 4: parsaclicib + itacitinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA given Parsaclisib its stamp of approval?
"Given the Phase 2 status, our team at Power has evaluated Parsaclisib's safety as a score of 2. Currently, there is some data affirming its security but no studies yet that have proven efficacy."
How much healthcare infrastructure is being utilized for this research endeavor?
"At the moment, 26 medical facilities are running this clinical trial. Aside from Long Beach, Kansas City and Seattle, there are 23 other sites in various cities across the nation. For ease of access for participants it is encouraged to select a location closest to you."
Is enrollment for the trial still available to interested participants?
"Affirmative. The clinical trial directory hosted on the governmental website highlights that this research has been open for applications since August 3rd 2020 and is currently in search of 200 participants across 26 facilities."
What is the current capacity for participants in this medical study?
"To meet the demands of this trial, 200 qualifying patients must be recruited. Incyte Corporation will be handling operations from two locations: Innovative Clinical Research Institute in Long Beach, California and Saint Luke'S Hospital of Kansas City in Missouri."
What evidence exists of Parsaclisib being examined in other scientific experiments?
"Currently, there are 39 ongoing clinical trials focused on Parsaclisib; four of them in their final stage. These studies have been established mainly in Rozzano but also span 1280 other locations worldwide."
Has this type of experiment been conducted previously or is it a pioneering endeavor?
"Presently, 39 research trials involving Parsaclisib are underway across 137 cities and 28 states. This drug was initially tested in 2013, when Incyte Corporation sponsored a trial with 121 participants that completed Phase 1 of the approval process. Since then, 20 separate studies have been carried out."
Share this study with friends
Copy Link
Messenger